close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

1.260 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
Via ACCESSWIRE
InvestorNewsBreaks – Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) Releases Pricing of Underwritten Public Offering to Total Estimated $15M
Via Investor Brand Network
News headline image
Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
Via ACCESSWIRE
News headline image
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
News headline image
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today